Tags

Type your tag names separated by a space and hit enter

Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation.
Fertil Steril 2011; 95(6):2024-8FS

Abstract

OBJECTIVE

To assess whether the clinical pregnancy rate of patients treated with recombinant FSH and IUI can be improved by the addition of a GnRH antagonist.

DESIGN

Prospective, controlled study.

SETTING

Reproductive medicine clinic.

PATIENT(S)

Ninety-three patients with primary or secondary infertility.

INTERVENTION(S)

Patients were allocated to controlled ovarian stimulation with recombinant FSH (50-150 IU/d) only (control group, n=45) or to recombinant FSH (50-150 IU/d) plus ganirelix (0.25 mg/d, starting when the leading follicle was ≥16 mm; n=48). A single insemination was performed 36 hours after hCG was given (10,000 IU, IM) in both groups. Both groups were allowed at least three cycles.

MAIN OUTCOME MEASURE(S)

Clinical pregnancy rate, premature luteinization rate, and follicular development.

RESULT(S)

Clinical pregnancy rate (22% vs. 11%), cumulative pregnancy rate (52% vs. 31%), and number of mature follicles (2.1±1.08 vs. 1.4±0.95) were statistically significantly higher in the ganirelix group compared with the control group. The premature luteinization rate was significantly lower in the ganirelix group (1.7% vs. 17.5%).

CONCLUSION(S)

The use of a GnRH antagonist in conjunction with controlled ovarian stimulation and IUI significantly increases pregnancy rates and reduces the incidence of premature luteinization.

Authors+Show Affiliations

Second Department of Obstetrics and Gynecology, Aretaieio Hospital, University of Athens, Athens, Greece. p_bakas@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

21334613

Citation

Bakas, Panagiotis, et al. "Role of Gonadotropin-releasing Hormone Antagonist in the Management of Subfertile Couples With Intrauterine Insemination and Controlled Ovarian Stimulation." Fertility and Sterility, vol. 95, no. 6, 2011, pp. 2024-8.
Bakas P, Konidaris S, Liapis A, et al. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. Fertil Steril. 2011;95(6):2024-8.
Bakas, P., Konidaris, S., Liapis, A., Gregoriou, O., Tzanakaki, D., & Creatsas, G. (2011). Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. Fertility and Sterility, 95(6), pp. 2024-8. doi:10.1016/j.fertnstert.2011.01.167.
Bakas P, et al. Role of Gonadotropin-releasing Hormone Antagonist in the Management of Subfertile Couples With Intrauterine Insemination and Controlled Ovarian Stimulation. Fertil Steril. 2011;95(6):2024-8. PubMed PMID: 21334613.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. AU - Bakas,Panagiotis, AU - Konidaris,Sokratis, AU - Liapis,Angelos, AU - Gregoriou,Odyseas, AU - Tzanakaki,Despoina, AU - Creatsas,Georgios, Y1 - 2011/02/19/ PY - 2010/11/23/received PY - 2011/01/25/revised PY - 2011/01/26/accepted PY - 2011/2/22/entrez PY - 2011/2/22/pubmed PY - 2011/6/22/medline SP - 2024 EP - 8 JF - Fertility and sterility JO - Fertil. Steril. VL - 95 IS - 6 N2 - OBJECTIVE: To assess whether the clinical pregnancy rate of patients treated with recombinant FSH and IUI can be improved by the addition of a GnRH antagonist. DESIGN: Prospective, controlled study. SETTING: Reproductive medicine clinic. PATIENT(S): Ninety-three patients with primary or secondary infertility. INTERVENTION(S): Patients were allocated to controlled ovarian stimulation with recombinant FSH (50-150 IU/d) only (control group, n=45) or to recombinant FSH (50-150 IU/d) plus ganirelix (0.25 mg/d, starting when the leading follicle was ≥16 mm; n=48). A single insemination was performed 36 hours after hCG was given (10,000 IU, IM) in both groups. Both groups were allowed at least three cycles. MAIN OUTCOME MEASURE(S): Clinical pregnancy rate, premature luteinization rate, and follicular development. RESULT(S): Clinical pregnancy rate (22% vs. 11%), cumulative pregnancy rate (52% vs. 31%), and number of mature follicles (2.1±1.08 vs. 1.4±0.95) were statistically significantly higher in the ganirelix group compared with the control group. The premature luteinization rate was significantly lower in the ganirelix group (1.7% vs. 17.5%). CONCLUSION(S): The use of a GnRH antagonist in conjunction with controlled ovarian stimulation and IUI significantly increases pregnancy rates and reduces the incidence of premature luteinization. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/21334613/Role_of_gonadotropin_releasing_hormone_antagonist_in_the_management_of_subfertile_couples_with_intrauterine_insemination_and_controlled_ovarian_stimulation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(11)00246-9 DB - PRIME DP - Unbound Medicine ER -